A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.
Gerry Wright, a professor in the Department of Biochemistry and Biomedical Sciences at McMaster University in collaboration with colleagues at the John Innes Centre in Norwich, and the University of Cambridge in the UK, have identified the specific mechanism that triggers resistance to vancomycin.
The discovery reveals new understanding about what is happening at the molecular level in vancomycin resistance. It also represents an essential first step in developing new antibiotics that can evade the sensing mechanism of bacteria and overcome resistance.
The research, funded in part by the Canadian Institutes of Health Research and the Canada Research Chairs program, will be published online in the high-impact journal Nature Chemical Biology on April 11, 2010.
"Vancomycin is the antibiotic of last resort and is only given when all other treatments fail," said Wright, who holds the Canada Research Chair in Molecular Studies of Antibiotics and an endowed research Chair in Infection and Anti-Infective Research.
"For years it was thought that resistance would be slow to emerge since vancomycin works in an unusual way. But with the widespread use of the drug to treat infections caused by the hospital superbug MRSA, it has become a serious clinical problem."
MRSA is the short-form for methicillin-resistant staphylococcus aureus, a bacterial infection that is highly resistant to some antibiotics. MRSA bacteria are responsible for a large percentage of hospital-acquired staph infections, but may also be acquired in the community.
Vancomycin is used to treat enterococcal infections that develop in patients following abdominal surgery. Enterococcal bacteria first developed resistance to vancomycin in 1986 and the first case of vancomycin-resistant MRSA (VMRSA) was reported in 2002.
For 20 years, scientists around the world have debated whether bacteria sense the drug itself to trigger resistance or whether they sense the impact it has on the cell wall of bacteria.
Most antibiotics work by inhibiting an enzyme but vancomycin binds to cell wall building blocks, causing a weakness in the structure of the cell wall so the cell bursts and dies.
Some scientists believed that bacteria detect the cell wall degradation to trigger resistance. Others argued that bacteria detect the presence of the drug directly.
Wright and his team studied the vancomycin-resistance mechanism in the harmless soil bacteria Streptomyces coelicolor.
The scientists showed that bacteria detect vancomycin itself. They also conducted preliminary experiments that suggest the same mechanism exists in disease causing bacteria.
"We have finally cracked the alarm system used by bacteria, and hopefully new antibiotics can be developed that don't set it off," said Mark Buttner, a study collaborator and senior scientist at the John Innes Centre.
Marc Ouellette, scientific director of the Institute of Infection and Immunity at the Canadian Institutes for Health Research (CIHR), said the research findings shed new light on the antibiotic resistance issue.
"Thousands of Canadians die every year from antibiotic-resistant infections," Ouellette said. "This issue has long been a priority of the CIHR and this exciting work expands our understanding of how bacteria develop resistance to antibiotics. It lays the groundwork for developing new therapies to prevent and treat antibiotic-resistant infections."
Additional research support was received from the Biotechnology and Biological Sciences Research Council of the UK, the Royal Society and the Medical Research Council (UK).
A photo of Dr. Wright can be downloaded at http://fhs.mcmaster.ca/media/media_20100409.html
For more information, please contact:Gerry Wright, PhD, professor, Department of Biochemistry and Biomedical Sciences at McMaster University
(289) 439-0325 or email@example.comSusan Emigh, Director, Health Sciences Public Relations, McMaster University
905-525-9140, ext. 22169, firstname.lastname@example.org
Susan Emigh | EurekAlert!
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Physics and Astronomy
08.12.2016 | Health and Medicine
08.12.2016 | Life Sciences